<DOC>
	<DOCNO>NCT00088790</DOCNO>
	<brief_summary>Purpose study ass safety tolerability AZD5438 give orally patient advance solid malignancy A review emerge clinical tolerability exposure data study conjunction preclinical available clinical pharmacodynamic data relate AZD5438 , lead decision AstraZeneca development AZD5438 potential anti-cancer agent would discontinue .</brief_summary>
	<brief_title>AZD5438 Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Advanced solid malignancy Cancer refractory standard treatment standard therapy exit Radiotherapy within 3 week start treatment Investigational product within last 3 week Systemic cytotoxic anticancer therapy within last 3 week Any significant clinical disorder make undesirable patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>advanced , solid , malignancy</keyword>
</DOC>